A decade of radiomics research: are images really data or just patterns in the noise?

Daniel Pinto dos Santos¹ • Matthias Dietzel² • Bettina Baessler³

Since Lambin et al first coined the term radiomics in early 2012, almost a decade has passed [1, 2]. At that time, medical imaging and automated image analysis had already seen significant advances (and certainly have seen more innovation since then), and the concept seemed promising. In radiomics research, radiological image data are processed in order to extract large amounts of quantitative image features, which are subsequently analyzed to identify meaningful patterns and novel imaging biomarkers [3]. In most cases, radiomics is applied to oncological imaging, e.g., to support discrimination of histological tumor subtypes, predict treatment response, and consequently support more individualized therapy regimes [4]. Understandably, research interest has been unbroken since then, and numerous studies have been published discussing the application of radiomics in various settings (Fig. 1). Coming close to a decade of research in radiomics, it might be worthwhile taking a look at what results have been achieved and what has been translated into clinical use.

At first sight, it seems that radiomics research could potentially have a huge impact on clinical routine. Recently, various studies addressing interesting clinical scenarios have been published. For instance, in a study published by Cui et al, a radiomics model was proposed to predict complete response to chemoradiotherapy in patients with locally advanced rectal cancer [5]. In another study, Baessler et al showed that a radiomics model could potentially differentiate between benign and malignant lymph nodes after chemoradiotherapy for metastatic germ cell tumors [6]. In both studies, it could be argued that radical oncological resection (i.e., proctectomy in the first, and retroperitoneal lymph node dissection in the latter case) could carry significant peri- and postoperative morbidity. Hence, reducing overtreatment by incorporating the results of such radiomics models in clinical decision-making could be beneficial—if not in all, then at least in selected cases. Nevertheless, it seems that despite the considerable number of publications on the subject, translation of such encouraging findings into clinical application is yet to happen. There are certainly various factors that play a role here, but a few important challenges stand out, which should be considered in future radiomics studies (Table 1).

First of all, a significant proportion of the published studies on applications of radiomics are of insufficient quality. This is of course a bold statement and should not be said lightly. Recently, Park et al carried out a detailed analysis of multiple studies and assessed their methodological quality using the radiomics quality score (RQS), as well as how results were reported according to the Transparent Reporting of a
Table 1 Key considerations for study design

| Consideration                  | Description                                                                                                                                 |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| **Selected features**          | Should clearly be described, name selected features, ideally along with information on how those were calculated. Instances where features like first order statistics such as “max volume of ROI” or “mean value in ROI” are selected do not necessarily qualify as radiomics and could also be obtained by “traditional” measurements. |
| **Model building**             | Careful consideration of all potential pitfalls limiting the model’s generalizability (i.e., inter- and intra-reader testing of the segmentations, testing for test-retest stability, homogenizing gray level intensities and pixel spacing) and statistical validity is needed. |
| **Selected model**             | The potentially best model should clearly be described. E.g., for simple models give equation with features and parameters, for more complex models make model accessible to other researchers so that results can be independently validated or further studies can be built upon those. |
| **Model validation**           | Selected models should be validated on an independent test set that was set aside before training the algorithm. Sampling method used should be clearly described (e.g., randomized stratified sampling). |
| **Model performance**          | Clinically meaningful performance metrics should be provided, such as PPV, NPV or F metrics. Depending on the incidence of disease even with a high AUC/sensitivity/specificity the PPV might be low, thus limiting its clinical usefulness. Also, the model should be benchmarked in comparison to expert human readers or models built on known clinical characteristics (e.g., size, LIRADS, laboratory results). |
| **Intended clinical use**      | It should be clearly stated which purpose the model could serve and what clinical need it serves. E.g., while a model might discriminate between two tumor stages, if no potential of stratification (due to missing alternatives or disproportionate risk of harming the patient if treatment is changed) is given, clinical usefulness may be limited. |
| **Impact on outcome**          | If a proposed radiomics model has been previously described and its results are reproducible and validated, outcome studies should carefully be designed to prove the model’s utility in clinical practice aiming to benefit the patient’s outcome. In order to move the field forward, there is an urgent need for prospective trials to demonstrate the impact of radiomics on patient outcome. |

Although radiomics research holds the potential to positively impact patient management and outcome, scientific rigor is needed in order to prove the benefits beyond reasonable doubt [7].
multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist [8]. The results were—to put it mildly—sobering. With a mean RQS score of only 26.1% and a mean adherence rate to the TRIPOD checklist of only 56.8%, there is obviously a lot room for improvement. These findings should, however, not be intended to devalue existing research, but rather be taken as an eye-opener encouraging us to strive for the highest possible scientific rigor—from the design of the studies all the way through the review and publication process. An open, self-reflecting discussion may be needed to analyze, why and how such findings come to be. Among the first steps, one possible approach could be to require authors and reviewers to follow checklists such as the aforementioned or the recently proposed Checklist for Artificial Intelligence in Medical Imaging [9].

Secondly, given that most approaches to radiomics rely on the analysis of distribution of gray values in a specified region or volume of interest (ROI/VOI), the inherent problem of medical imaging needs to be carefully considered. For example, while one specific scanner might lead to reproducible gray value distributions in a single patient at a single time point when the analysis is carried out by a single reader, this is not necessarily the case when another patient with the exact same pathology is scanned on a different machine, the same patient is scanned at different time points or even when different readers assess the images and place the ROI/VOI. In the worst cases, we as radiologists might be able to see the patterns beyond the noise, but an algorithm that performs complex calculations might easily be derailed by just the tiniest amount of noise [10, 11]. To further add to this complexity, in most cases, complex statistical approaches and machine learning are used to build prediction models based on radiomics features which come with their own challenges [12, 13]. To tackle these issues and avoid getting lost in a reproducibility crisis, careful methodological and statistical consideration of potential pitfalls is crucial [7, 14].

Lastly, in order to close the “translational gap” of radiomics, it will be crucial to obtain higher evidence levels and move beyond exploratory retrospective studies. Carefully designed prospective, multicenter, randomized controlled trials and data sharing will be needed in the future to prove the clinical usefulness of radiomics and subsequently improved patient outcomes in a setting as close to clinical routine as possible [15, 16].

Of course, neither was Rome built in one day, nor did cardiac CT find its way to clinical routine just shortly after the first developments in 1976 [17]. Nevertheless, in order to move the field of radiomics forward, future research should focus on the challenges mentioned above (Table 1). It might not be an easy task, but the effort could prove worthwhile—or as a prominent political figure might have said, had he done research in radiomics: “We should choose to bring radiomics to clinical routine in this decade, not because it is easy, but because it is hard; because the goal should be to serve our patients and improve outcomes”.

**Funding information** Open Access funding provided by Projek D.EAL.

**Compliance with ethical standards**

**Guarantor** The scientific guarantor of this publication is Dr. Daniel Pinto dos Santos, University Hospital of Cologne (daniel.pinto-dos-santos@uk-koeln.de).

**Conflict of interest** The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

**Statistics and biometry** No complex statistical methods were necessary for this paper.

**Informed consent** Not applicable.

**Ethical approval** Not applicable.

**Methodology**

- editorial

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446
2. Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762
3. Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278(2):563–577
4. Savadjiev P, Chong J, Dohan A et al (2019) Image-based biomarkers for solid tumor quantification. Eur Radiol 29(10):5431–5440
5. Cui Y, Yang X, Shi Z et al (2019) Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 29(3):1211–1220
6. Baessler B, Nestler T, Pinto dos Santos D et al (2020) Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Eur Radiol 30(4):2334–2345

© Springer
7. Zwanenburg A (2019) Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. Eur J Nucl Med Mol Imaging 46(13): 2638–2655
8. Park JE, Kim D, Kim HS, et al. (2019) Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement. Eur Radiol 30(1):523–536
9. Mongan J, Moy L, Kahn CE (2020) Checklist for artificial intelligence in medical imaging (CLAIM): a guide for authors and reviewers. Radiol Artif Intell 2(2):e200029
10. Molina D, Pérez-Beteta J, Martínez-González A, et al. (2017) Lack of robustness of textural measures obtained from 3D brain tumor MRIs impose a need for standardization. PLoS One 12(6): e0178843
11. Berenguer R, del Rosario Pastor Juan M, Canales-Vázquez J et al. (2018) Radiomics of CT features may be nonreproducible and redundant: influence of CT acquisition parameters. Radiology. 288(2):407–415
12. Foster KR, Koprowski R, Skufca JD (2014) Machine learning, medical diagnosis, and biomedical engineering research - commentary. Biomed Eng Online 13(1):94
13. Molina-García D, Vera-Ramírez L, Pérez-Beteta J, Arana E, Pérez-García VM (2019) Prognostic models based on imaging findings in glioblastoma: human versus machine. Sci Rep 9(1):5982
14. Di Leo G, Sardanelli F (2020) Statistical significance: p value, 0.05 threshold, and applications to radiomics—reasons for a conservative approach. Eur Radiol Exp 4(1):18
15. Dewey M, Bossert M, Dodd JD, Thun S, Kressel HY (2019) Clinical imaging research: higher evidence, global collaboration, improved reporting, and data sharing are the grand challenges. Radiology. 291(3):547–552
16. Sardanelli F, Ali M, Hunink MG, Houssami N, Sconfienza LM, Di Leo G (2018) To share or not to share? Expected pros and cons of data sharing in radiological research. Eur Radiol 28(6):2328–2335
17. Ter-Pogossian M, Weiss E, Coleman R, Sobel B (1976) Computed tomography of the heart. AJR Am J Roentgenol 127(1):79–90

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.